La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
SciVision Biotech Bilan de santé
Santé financière contrôle des critères 6/6
SciVision Biotech has a total shareholder equity of NT$1.7B and total debt of NT$206.1M, which brings its debt-to-equity ratio to 12.1%. Its total assets and total liabilities are NT$2.3B and NT$632.9M respectively. SciVision Biotech's EBIT is NT$232.4M making its interest coverage ratio -19.8. It has cash and short-term investments of NT$924.7M.
Informations clés
12.1%
Ratio d'endettement
NT$206.13m
Dette
| Ratio de couverture des intérêts | -19.8x |
| Argent liquide | NT$924.74m |
| Fonds propres | NT$1.70b |
| Total du passif | NT$632.94m |
| Total des actifs | NT$2.33b |
Mises à jour récentes de la santé financière
SciVision Biotech (TWSE:1786) Seems To Use Debt Rather Sparingly
Jun 04
Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly
Apr 20Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly
Jan 18Recent updates
SciVision Biotech's (TWSE:1786) Upcoming Dividend Will Be Larger Than Last Year's
Jul 22SciVision Biotech (TWSE:1786) Has Announced That It Will Be Increasing Its Dividend To NT$2.50
Jun 28SciVision Biotech Inc.'s (TWSE:1786) 27% Price Boost Is Out Of Tune With Earnings
Jun 14SciVision Biotech (TWSE:1786) Seems To Use Debt Rather Sparingly
Jun 04Some Shareholders Feeling Restless Over SciVision Biotech Inc.'s (TWSE:1786) P/E Ratio
Apr 01Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly
Apr 20SciVision Biotech (TPE:1786) Is Looking To Continue Growing Its Returns On Capital
Apr 02Can You Imagine How SciVision Biotech's (TPE:1786) Shareholders Feel About The 33% Share Price Increase?
Mar 15Read This Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend
Feb 25Could The Market Be Wrong About SciVision Biotech Inc. (TPE:1786) Given Its Attractive Financial Prospects?
Feb 05Here's Why SciVision Biotech (TPE:1786) Can Manage Its Debt Responsibly
Jan 18Will The ROCE Trend At SciVision Biotech (TPE:1786) Continue?
Jan 01
SciVision Biotech (TPE:1786) Shareholders Booked A 80% Gain In The Last Three Years
Dec 14Key Things To Consider Before Buying SciVision Biotech Inc. (TPE:1786) For Its Dividend
Nov 25Analyse de la situation financière
Passif à court terme: 1786's short term assets (NT$1.2B) exceed its short term liabilities (NT$362.3M).
Passif à long terme: 1786's short term assets (NT$1.2B) exceed its long term liabilities (NT$270.6M).
Historique et analyse du ratio d'endettement
Niveau d'endettement: 1786 has more cash than its total debt.
Réduire la dette: 1786's debt to equity ratio has reduced from 22.1% to 12.1% over the past 5 years.
Couverture de la dette: 1786's debt is well covered by operating cash flow (145.3%).
Couverture des intérêts: 1786 earns more interest than it pays, so coverage of interest payments is not a concern.